Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies

Biochemical and Biophysical Research Communications

Volumn 486, Issue 4, 2017, Pages 985-991

  Grujic, Ognjen ^a   Stevens, Jennitte ^b   Chou, Robert Y T ^b   Weiszmann, Jennifer V ^b   Sekirov, Laura ^a   Thomson, Christy ^a   Badh, Anita ^a   Grauer, Stephanie ^a   Chan, Brian ^a   Graham, Kevin ^b   Manchulenko, Kathy ^a   Dillon, Thomas M ^b   Li, Yang ^b   Foltz, Ian N ^a  

^a Amgen British Columbia   (Canada)

^b AMGEN INC   (United States)

Author keywords

Agonist; Antibody isoform; CD200R; Subclass; klotho

Indexed keywords

BETA KLOTHO ANTIBODY; CD200 RECEPTOR; CD200 RECEPTOR ANTIBODY; CELL SURFACE RECEPTOR; DISULFIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; KLOTHO PROTEIN; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; CD200R1 PROTEIN, HUMAN; ISOPROTEIN; KLB PROTEIN, HUMAN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN;

ADIPOCYTE; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHO CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HINGE REGION; HUMAN; HUMAN CELL; HYBRIDOMA; ION EXCHANGE CHROMATOGRAPHY; LIGHT CHAIN; PRIORITY JOURNAL; U-937 CELL LINE; ANIMAL; CHEMISTRY; CRICETULUS; EPITOPE MAPPING; IMMUNOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CHO CELLS; CRICETULUS; DISULFIDES; EPITOPE MAPPING; MEMBRANE PROTEINS; PROTEIN ISOFORMS; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85016395043     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.03.145     Document Type: Article

References (28)

1. [1] Foltz, I.N., Gunasekaran, K., King, C.T., Discovery and bio-optimization of human antibody therapeutics using the XenoMouse(R) transgenic mouse platform. Immunol. Rev. 270 (2016), 51–64.
2. [2] Scott, A.M., Wolchok, J.D., Old, L.J., Antibody therapy of cancer. Nat. Rev. Cancer 12 (2012), 278–287.
3. [3] Chan, A.C., Carter, P.J., Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10 (2010), 301–316.
4. [4] Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008), 34–47.
5. [5] Foltz, I.N., Karow, M., Wasserman, S.M., Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation 127 (2013), 2222–2230.
6. [6] Irani, V., Guy, A.J., Andrew, D., Beeson, J.G., Ramsland, P.A., Richards, J.S., Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol. Immunol. 67 (2015), 171–182.
7. [7] Carter, P.J., Potent antibody therapeutics by design. Nat. Rev. Immunol. 6 (2006), 343–357.
8. [8] Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., Lambrecht, B.N., The function of Fcgamma receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14 (2014), 94–108.
9. [9] Schuurman, J., Perdok, G.J., Gorter, A.D., Aalberse, R.C., The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol. Immunol. 38 (2001), 1–8.
10. [10] van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W.K., Martinez-Martinez, P., Vermeulen, E., den Bleker, T.H., Wiegman, L., Vink, T., Aarden, L.A., De Baets, M.H., van de Winkel, J.G., Aalberse, R.C., Parren, P.W., Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 (2007), 1554–1557.
11. [11] Salfeld, J.G., Isotype selection in antibody engineering. Nat. Biotechnol. 25 (2007), 1369–1372.
12. [12] Liu, Y.D., Chen, X., Enk, J.Z., Plant, M., Dillon, T.M., Flynn, G.C., Human IgG2 antibody disulfide rearrangement in vivo. J. Biol. Chem. 283 (2008), 29266–29272.
13. [13] Wypych, J., Li, M., Guo, A., Zhang, Z., Martinez, T., Allen, M.J., Fodor, S., Kelner, D.N., Flynn, G.C., Liu, Y.D., Bondarenko, P.V., Ricci, M.S., Dillon, T.M., Balland, A., Human IgG2 antibodies display disulfide-mediated structural isoforms. J. Biol. Chem. 283 (2008), 16194–16205.
14. [14] Dillon, T.M., Ricci, M.S., Vezina, C., Flynn, G.C., Liu, Y.D., Rehder, D.S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., Varnum, B., Wypych, J., Balland, A., Bondarenko, P.V., Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J. Biol. Chem. 283 (2008), 16206–16215.
15. [15] Liu, Y.D., Wang, T., Chou, R., Chen, L., Kannan, G., Stevenson, R., Goetze, A.M., Jiang, X.G., Huang, G., Dillon, T.M., Flynn, G.C., IgG2 disulfide isoform conversion kinetics. Mol. Immunol. 54 (2013), 217–226.
16. [16] Ashkenazi, A., Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 (2008), 1001–1012.
17. [17] Wilson, N.S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., Ross, S., Vernes, J.M., Lu, Y., Adams, C., Offringa, R., Kelley, B., Hymowitz, S., Daniel, D., Meng, G., Ashkenazi, A., An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19 (2011), 101–113.
18. [18] White, A.L., Chan, H.T., French, R.R., Willoughby, J., Mockridge, C.I., Roghanian, A., Penfold, C.A., Booth, S.G., Dodhy, A., Polak, M.E., Potter, E.A., Ardern-Jones, M.R., Verbeek, J.S., Johnson, P.W., Al-Shamkhani, A., Cragg, M.S., Beers, S.A., Glennie, M.J., Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 27 (2015), 138–148.
19. [19] Jenmalm, M.C., Cherwinski, H., Bowman, E.P., Phillips, J.H., Sedgwick, J.D., Regulation of myeloid cell function through the CD200 receptor. J. Immunol. 176 (2006), 191–199.
20. [20] Mihrshahi, R., Barclay, A.N., Brown, M.H., Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J. Immunol. 183 (2009), 4879–4886.
21. [21] Zhang, S., Cherwinski, H., Sedgwick, J.D., Phillips, J.H., Molecular mechanisms of CD200 inhibition of mast cell activation. J. Immunol. 173 (2004), 6786–6793.
22. [22] Zhang, J., Li, Y., Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov. Today 19 (2014), 579–589.
23. [23] Foltz, I.N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J.S., Nuanmanee, N., Gupte, J., Komorowski, R., Sekirov, L., Hager, T., Arora, T., Ge, H., Baribault, H., Wang, F., Sheng, J., Karow, M., Wang, M., Luo, Y., McKeehan, W., Wang, Z., Veniant, M.M., Li, Y., Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med., 4, 2012 162ra153.
24. [24] Shukla, A.A., Hubbard, B., Tressel, T., Guhan, S., Low, D., Downstream processing of monoclonal antibodies–application of platform approaches. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 848 (2007), 28–39.
25. [25] Estes, B., Hsu, Y.R., Tam, L.T., Sheng, J., Stevens, J., Haldankar, R., Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system. Biotechnol. Prog. 31 (2015), 258–267.
26. [26] White, A.L., Chan, H.T., French, R.R., Beers, S.A., Cragg, M.S., Johnson, P.W., Glennie, M.J., FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol. Immunother. 62 (2013), 941–948.
27. [27] Yie, J., Wang, W., Deng, L., Tam, L.T., Stevens, J., Chen, M.M., Li, Y., Xu, J., Lindberg, R., Hecht, R., Veniant, M., Chen, C., Wang, M., Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem. Biol. Drug Des. 79 (2012), 398–410.
28. [28] Green, L.L., Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231 (1999), 11–23.